皮鲁酸烯酸透症是持续性白血病干细胞中的一个可向的脆弱性
Kevin M Rattigan1, Zuzana Brabcova1, Daniele Sarnello1
1Wolfson Wohl Cancer Research Centre; Institute of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH, UK.
Nature communications
|August 17, 2023
概括
慢性骨髓性白血病 (CML) 中的白血病干细胞表现出持续的代谢变化,特别是增加的酸盐厌血症,即使在TKI治疗后. 通过MPC抑制剂向这种代谢脆弱性显示出对Imatinib耐药CML的承诺.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 白血病干细胞生物学
背景情况:
- 不调节的氧化代谢是白血病的特征.
- 氨酸激酶抑制剂 (TKIs) 改善慢性髓性白血病 (CML) 的存活率,但不会消除白血病干细胞 (LSCs).
- 用TKI治疗的CML低血压细胞的代谢状态尚不清楚.
研究的目的:
- 研究患者衍生的CML LSCs中的代谢适应.
- 确定TKI治疗是否影响LSC代谢放松调节.
- 在CML LSC中确定潜在的治疗点.
主要方法:
- 通过使用临床相关的测试生成多omics数据集.
- 稳定的同位素辅助代谢.
- 皮鲁酸的遗传性除. 皮鲁酸的缩症.
- 临床前CML模型使用MSDC-0160,一种MPC1/2抑制剂.
主要成果:
- 慢性肌痛性慢性硬性硬性瘤通过 mitochondrial pyruvate carrier 1/2 (MPC1/2) 和 pyruvate carboxylase (PC) 活动的升高而增加了 pyruvate 厌氧症.
- 伊马替尼布治疗逆转了一些代谢重编程,但没有影响pyruvate的阿纳普勒索斯.
- 皮鲁酸的遗传抑制使得CML细胞对伊马替尼布敏感.
- MSDC-0160抑制了pyruvate的阿纳普勒索斯,并向了对伊马替尼布抗性CML的乳腺癌细胞.
结论:
- 皮鲁酸性厌敏症是CMLLSCs中持续的代谢脆弱性,不受伊马替尼的影响.
- 针对皮鲁酸,特别是像MSDC-0160这样的MPC抑制剂,为耐伊马替尼布的CML提供了潜在的治疗策略.
- 这突出了消除残留CML疾病的新型治疗途径.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
172
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
